

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
PEYMAN et al.) Group Art Unit: Unassigned
Serial No.: Unassigned) Examiner: Unassigned
Filed: Concurrently herewith)
For: NEW GUANIDINE AND AMIDINE)
DERIVATIVES AS FACTOR Xa)
INHIBITORS)

Commissioner for Patents and Trademarks
Washington, DC 20231


Sir:

PRELIMINARY AMENDMENT

Prior to the examination of the above application, please amend this application
as follows:

IN THE CLAIMS:

1. (Amended) A compound of the formula I,



wherein

1000442-12001
105027-2240001

- R_0 is
1. phenyl, wherein phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^2 or
 2. a mono- or bicyclic 5- to 10-membered heteroaryl containing one or two nitrogen atoms as ring heteroatoms, wherein heteroaryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^2 ,

- R^2 is
1. $-\text{NO}_2$,
 2. halogen,
 3. $-\text{CN}$,
 4. $-\text{OH}$,
 5. $-\text{NH}_2$,
 6. $(\text{C}_1\text{-C}_8)\text{-alkyloxy-}$, wherein alkyloxy is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, amino group, hydroxy group or methoxy group, or
 7. $(\text{C}_1\text{-C}_8)\text{-alkyl}$, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, amino group, hydroxy group or methoxy group,

Q and Q' are independently of one another identical or different and are a direct bond, $-\text{O}-$, $-\text{S}-$, $-\text{NR}^{10}-$, $-\text{C}(\text{O})\text{NR}^{10}-$, $-\text{NR}^{10}\text{C}(\text{O})-$, $-\text{S}(\text{O})-$, $-\text{SO}_2-$, $-\text{NR}^{10}\text{-SO}_2-$, $-\text{SO}_2\text{-NR}^{10}$ - [oder] or $-\text{C}(\text{O})-$;

R^{10} is hydrogen atom or $(\text{C}_1\text{-C}_4)\text{-alkyl-}$,


- X is
1. a direct bond,
 2. $(\text{C}_1\text{-C}_6)\text{-alkylene}$, wherein alkylene is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, amino group or a hydroxy group,
 3. $(\text{C}_3\text{-C}_6)\text{-cycloalkylene}$, wherein cycloalkylene is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, amino group or a hydroxy group,

provided that at least one of Q, X and Q' is not a direct bond,

the substructure of formula III

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com



(III)

- is 1. a mono- or bicyclic 5- to 10-membered carbocyclic aryl group, wherein said 5- to 10-membered carbocyclic aryl group is unsubstituted or mono-, di- or trisubstituted independently of one another by R^1 ,
2. phenyl, wherein phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^1 ,
3. a mono- or bicyclic 5- to 10-membered heterocyclic group (Het), containing one or more heteroatoms as ring heteroatoms, such as nitrogen, sulfur or oxygen, wherein said Het group is unsubstituted or mono-, di- or trisubstituted independently of one another by R^1 , or
4. pyridyl, wherein pyridyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^1 ,

wherein D is carbon, oxygen, sulfur or nitrogen,

- R^1 is
1. halogen,
 2. $-NO_2$,
 3. $-CN$,
 4. $R^{11}R^{12}N-$, wherein $R^{11}R^{12}$ independently of one another are hydrogen atom, (C_1-C_4) -alkyl- or (C_1-C_6) -acyl-,
 5. (C_1-C_8) -alkylamino-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{13} ,
 6. $-OH$,
 7. $-SO_2-NH_2$,
 8. (C_1-C_8) -alkyloxy-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{13} ,
 9. (C_6-C_{14}) -aryl, wherein aryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{13} ,
 10. (C_1-C_8) -alkyl-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{13} ,

11. hydroxycarbonyl-(C₁-C₈)-alkylureido-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
12. (C₁-C₈)-alkyloxycarbonyl-(C₁-C₈)-alkylureido-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
13. (C₁-C₈)-alkylsulfonyl-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³, or
14. -C(O)-NR¹⁴R¹⁵, wherein R¹⁴R¹⁵ independently of one another are hydrogen atom or (C₁-C₄)-alkyl-, or


two R¹ residues bonded to adjacent ring carbon atoms together with the carbon atoms to which they are bonded form an aromatic ring condensed to the ring depicted in formula I, where the ring formed by the two R¹ residues is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³, R¹¹ and R¹² together with the nitrogen atom to which they are bonded form a saturated or unsaturated 5- to 6-membered monocyclic heterocyclic ring which in addition to the nitrogen atom carrying R¹¹ and R¹² can contain one or two identical or different ring heteroatoms chosen from oxygen, sulfur and nitrogen, and in which one or two of the ring carbon atoms can be substituted by oxo to form -C(O)- residue(s),

- R¹³ is
1. halogen,
 2. -NO₂,
 3. -CN,
 4. -OH,
 5. (C₁-C₈)-alkyl-,
 6. (C₁-C₈)-alkyloxy-,
 7. -CF₃ or
 8. -NH₂,


V is a residue of the formulae IIa, IIb, IIc, IId, IIe or II f,

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP


1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com




IIa




IIb




IIc



IIId



IIId



IIIf

wherein

L is is a direct bond or (C₁-C₃)-alkylene, wherein alkylene is unsubstituted or mono-, di- or trisubstituted independently of one another by A,

- A is
1. hydrogen atom,
 2. -C(O)-OH,
 3. -C(O)-O-(C₁-C₄)-alkyl, wherein alkyl is unsubstituted or mono-, di- or tri- substituted independently of one another by -OH, -NH₂ or -(C₁-C₄)-alkoxy,
 4. -C(O)-NR⁴R⁵,
 5. (C₁-C₄)-alkyl-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by -OH, -NH₂ or -(C₁-C₄)-alkoxy,
 6. -SO₂-NH₂ or
 7. -SO₂-CH₃,

U is -NH₂, (C₁-C₄)-alkyl-, -NH-C(O)-O-(C₁-C₄)-alkyl or -NH-C(O)-O-(C₁-C₄)-alkyl-aryl,

M is hydrogen atom, (C₁-C₃)-alkyl- or -OH,

R⁴ and R⁵ are independently of one another identical or different and are

1. hydrogen atom,

1000442-12001

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

2. (C₁-C₁₂)-alkyl-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³ as defined above,
3. (C₆-C₁₄)-aryl-(C₁-C₄)-alkyl-, wherein alkyl and aryl are unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³ as defined above,
4. (C₆-C₁₄)-aryl-, wherein aryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³ as defined above,
5. Het-, wherein Het- is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³ as defined above, or
6. Het-(C₁-C₄)-alkyl-, wherein alkyl and Het- are unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³ as defined above, or R⁴ and R⁵ together with the nitrogen atom to which they are bonded form a saturated 3- to 8-membered monocyclic heterocyclic ring which in addition to the nitrogen atom carrying R⁴ and R⁵ can contain one or two identical or different ring heteroatoms chosen from oxygen, sulfur and nitrogen; in all its stereoisomeric forms and mixtures thereof in any ratio, and its physiologically tolerable salts.

2. (Amended) A compound of formula I as claimed in claim 1, wherein R₀ is phenyl, wherein phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R², or pyridyl, wherein pyridyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R²,
R² is
 1. -NO₂,
 2. halogen,
 3. -CN,
 4. -OH,
 5. -NH₂,
 6. (C₁-C₄)-alkyloxy-, wherein alkyloxy is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, amino group, hydroxy group or methoxy group, or

7. $-(C_1-C_4)$ -alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, amino group, hydroxy group or methoxy group,

Q, Q', X, R¹, R¹¹ and R¹² are as defined in claim 1,

the substructure of formula III is

1. phenyl, wherein phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹, or
2. pyridyl, wherein pyridyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹,

wherein D is carbon or nitrogen,

- R¹³ is
1. halogen,
 2. $-NO_2$,
 3. $-CN$,
 4. $-OH$,
 5. (C_1-C_4) -alkyl-,
 6. (C_1-C_4) -alkyloxy-,
 7. $-CF_3$ or
 8. $-NH_2$,

R₁₀ is hydrogen atom or methyl,

V is a fragment of the formula IIa, IIb, IIc, IId, IIe or II f as defined above, wherein

L, U, M, R⁴ and R⁵ are as defined in claim 1, and

- A is
1. hydrogen atom,
 2. $-C(O)-OH$,
 3. $-C(O)-O-(C_1-C_4)$ -alkyl, wherein alkyl is unsubstituted or mono-, di- or tri- substituted independently of one another by $-OH$, $-NH_2$ or $-(C_1-C_4)$ -alkoxy,
 4. $-C(O)-NR^4R^5$ or
 5. (C_1-C_4) -alkyl-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by $-OH$, $-NH_2$ or $-(C_1-C_4)$ -alkoxy.

3. (Amended) A compound of the formula I as claimed in claim 1, wherein

R⁰ is phenyl, wherein phenyl is mono-, di- or trisubstituted independently of one another by R², or

pyridyl, wherein pyridyl is mono-, di- or trisubstituted independently of one another by R²,

- R² is
1. -NH₂,
 2. halogen,
 3. -CN,
 4. -OH,
 5. (C₁-C₄)-alkyloxy-, wherein alkyloxy is unsubstituted or substituted by an amino group, or
 6. -(C₁-C₄)-alkyl, wherein alkyl is unsubstituted or substituted by an amino group,

Q and Q' are independently of one another identical or different and are a direct bond, -O-, -C(O)NR¹⁰-, -NR¹⁰C(O)-; -NR¹⁰-SO₂-; or -SO₂-NR¹⁰-;

- X is
1. a direct bond or
 2. (C₁-C₄)-alkylene, wherein alkylene is unsubstituted or mono-, di- or tri-substituted independently of one another by halogen, amino group or a hydroxy group,

the substructure of formula III is

phenyl or pyridyl, wherein phenyl and pyridyl are unsubstituted or mono-, di- or trisubstituted independently of one another by R¹, and

D is carbon or nitrogen,

- R¹ is
1. halogen,
 2. -NO₂,
 3. -CN,
 4. -NH₂,
 5. (C₁-C₄)-alkylamino-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
 6. -OH,
 7. -SO₂-NH₂,
 8. (C₁-C₄)-alkyloxy-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,

9. (C₆-C₁₄)-aryl, wherein aryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
 10. (C₁-C₄)-alkyl-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
 11. (C₁-C₄)-alkylsulfonyl-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
 12. -C(O)-NR¹⁴R¹⁵, wherein R¹⁴R¹⁵ independently of one another are hydrogen atom or (C₁-C₄)-alkyl-,
 13. R¹¹R¹²N-, wherein R¹¹ and R¹² are as defined above, or
 14. -NR⁴R⁵,
- R¹³ is
1. halogen,
 2. -NO₂,
 3. -CN,
 4. -OH,
 5. (C₁-C₄)-alkyl-,
 6. (C₁-C₄)-alkyloxy-,
 7. -CF₃ or
 8. -NH₂,

R₁₀ is hydrogen atom or methyl,

V is a fragment of the formula IIa, IIb, IIc, IId, IIe or II f as defined above, wherein

L is a direct bond or (C₁-C₃)-alkylen-,

A is hydrogen atom, -C(O)-OH, -C(O)-O-(C₁-C₄)-alkyl, -C(O)-NR⁴R⁵ or (C₁-C₄)-alkyl-,

U is -NH₂, methyl, -NH-C(O)-O-(C₁-C₄)-alkyl or -NH-C(O)-O-(CH₂)-phenyl,

M is hydrogen atom, (C₁-C₃)-alkyl- or -OH, and

R⁴ and R⁵ are independently of one another hydrogen atom or (C₁-C₄)-alkyl-.

4. (Amended) A compound of formula I as claimed in claim 1, wherein

R₀ is phenyl or pyridyl, wherein phenyl and pyridyl independently from one another are mono-, di- or trisubstituted independently of one another by R²,

R² is

 1. halogen,
 2. -CN,

3. (C₁-C₄)-alkyloxy-, wherein alkyloxy is unsubstituted or substituted by halogen or an amino group, or
4. -(C₁-C₄)-alkyl, wherein alkyl is unsubstituted or substituted by an amino group or halogen,

Q and Q' are independently of one another identical or different and are a direct bond, -O-, -C(O)NR¹⁰-, -NR¹⁰C(O)-; -NR¹⁰-SO₂-; or -SO₂-NR¹⁰-;

X is -(C₁-C₃)-alkylen-, wherein alkylen is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, amino group or hydroxy group,

the substructure of formula III is

phenyl, wherein phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹, and

D is carbon

- R¹ is
1. halogen,
 2. -NO₂,
 3. -CN,
 4. -NH₂,
 5. (C₁-C₄)-alkylamino-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
 6. -OH,
 7. -SO₂-NH₂,
 8. (C₁-C₄)-alkyloxy-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
 9. (C₆-C₁₄)-aryl, wherein aryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
 10. (C₁-C₄)-alkyl-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
 11. (C₁-C₄)-alkylsulfonyl-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
 12. -C(O)-NR¹⁴R¹⁵, wherein R¹⁴R¹⁵ independently of one another are hydrogen atom or (C₁-C₄)-alkyl-,
 13. R¹¹R¹²N-, wherein R¹¹ and R¹² are as defined above, or
 14. -NR⁴R⁵,

100442-12001
2004-12-01

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

- R¹³ is
1. halogen,
 2. -CF₃,
 3. -NH₂,
 4. -OH,
 5. (C₁-C₄)-alkyl- or
 6. (C₁-C₄)-alkyloxy-,

R₁₀ is hydrogen atom, and

V is a fragment of the formula IIa, IIb, IIc or IId as defined above, wherein

L is a direct bond or (C₁-C₂)-alkylen-,

A is hydrogen atom, -C(O)-OH, -C(O)-O-(C₁-C₄)-alkyl, -C(O)-NR⁴R⁵ or (C₁-C₄)-alkyl,

U is -NH₂, methyl, -NH-C(O)-O-(C₁-C₄)-alkyl or -NH-C(O)-O-(CH₂)-phenyl,

M is hydrogen atom or (C₁-C₃)-alkyl-, and

R⁴ and R⁵ are independently of one another hydrogen atom or methyl.

5. (Amended) A compound of formula I as claimed in claim 1, wherein

R₀ is phenyl, wherein phenyl is mono-, di- or trisubstituted independently of one another by R²,

- R² is
1. halogen,
 2. (C₁-C₄)-alkyloxy-, wherein alkyloxy is unsubstituted or substituted by halogen or an amino group, or
 3. -(C₁-C₄)-alkyl, wherein alkyl is unsubstituted or substituted by an amino group or halogen,

Q and Q' are independently of one another identical or different and are a direct bond, -O-, -C(O)NR¹⁰-, -NR¹⁰C(O)-; -NR¹⁰-SO₂-; or -SO₂-NR¹⁰-;

X is -(C₁-C₃)-alkylen-,

the substructure of formula III is

phenyl, wherein phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹, and

D is carbon

- R¹ is
1. halogen,

2. $-\text{NO}_2$,
 3. $-\text{CN}$,
 4. $-\text{NH}_2$,
 5. $(\text{C}_1\text{-C}_4)\text{-alkylamino-}$, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{13} ,
 6. $-\text{OH}$,
 7. $-\text{SO}_2\text{-NH}_2$,
 8. $(\text{C}_1\text{-C}_4)\text{-alkyloxy-}$, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{13} ,
 9. $(\text{C}_1\text{-C}_4)\text{-alkyl-}$, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{13} ,
 10. $(\text{C}_1\text{-C}_4)\text{-alkylsulfonyl-}$, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{13} ,
 11. $-\text{C}(\text{O})\text{-NR}^{14}\text{R}^{15}$, wherein $\text{R}^{14}\text{R}^{15}$ independently of one another are hydrogen atom or $(\text{C}_1\text{-C}_2)\text{-alkyl-}$,
 12. $\text{R}^{11}\text{R}^{12}\text{N-}$, wherein R^{11} and R^{12} are as defined above, or
 13. $-\text{NR}^4\text{R}^5$,
- R^{13} is
1. halogen,
 2. $-\text{CF}_3$,
 3. $-\text{NH}_2$,
 4. $-\text{OH}$,
 5. $(\text{C}_1\text{-C}_4)\text{-alkyl-}$ or
 6. $(\text{C}_1\text{-C}_4)\text{-alkyloxy-}$,

R_{10} is hydrogen atom, and

V is a fragment of the formula IIa, IIb, IIc or IId as defined above, wherein

L is a direct bond or $(\text{C}_1\text{-C}_2)\text{-alkylen-}$,

A is hydrogen atom, $-\text{C}(\text{O})\text{-OH}$, $-\text{C}(\text{O})\text{-O-}(\text{C}_1\text{-C}_4)\text{-alkyl}$, $-\text{C}(\text{O})\text{-NR}^4\text{R}^5$ or $-(\text{C}_1\text{-C}_4)\text{-alkyl}$,

U is $-\text{NH}_2$, methyl, $-\text{NH-C}(\text{O})\text{-O-}(\text{C}_1\text{-C}_4)\text{-alkyl}$ or $-\text{NH-C}(\text{O})\text{-O-}(\text{CH}_2)\text{-phenyl}$,

M is hydrogen atom or methyl, and

R^4 and R^5 are independently of one another hydrogen atom or methyl.

6. (Amended) A compound of formula I as claimed in claim 1, wherein
- R_0 is phenyl, wherein phenyl is disubstituted independently of one another by R^2 ,
- R^2 is
1. halogen,
 2. (C_1-C_2) -alkyloxy-, wherein alkyloxy is unsubstituted or substituted by an amino group, or
 3. $-(C_1-C_4)$ -alkyl, wherein alkyl is unsubstituted or substituted by an amino group,

Q and Q' are independently of one another identical or different and are a direct bond or -O-,

X is $-CH_2-CH_2-$,

the substructure of formula III is

phenyl, wherein phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^1 , and

D is carbon,

- R^1 is
1. halogen,
 2. -OH,
 3. $-NH_2$,
 4. $-C(O)-NR^{14}R^{15}$, wherein $R^{14}R^{15}$ independently of one another are hydrogen atom or (C_1-C_2) -alkyl-,
 5. (C_1-C_3) -alkyloxy-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{13} , or
 6. (C_1-C_3) -alkyl-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{13} ,

R^{13} is fluorine or chlorine,

R_{10} is hydrogen atom, and

V is a fragment of the formula IIa, IIb, IIc or IId as defined above, wherein

L is a direct bond or (C_1-C_2) -alkylen-,

A is hydrogen atom, $-C(O)-OH$, $-C(O)-O-(C_1-C_4)$ -alkyl, $-C(O)-NR^4R^5$ or $-(C_1-C_4)$ -alkyl,

U is $-NH_2$, methyl, $-NH-C(O)-O-(C_1-C_4)$ -alkyl or $-NH-C(O)-O-(CH_2)$ -phenyl,

M is hydrogen atom, and


R^4 and R^5 are independently of one another hydrogen atom or methyl.

100442-2240001


FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

7. (Amended) A process for the preparation of a compound of the formula I as claimed in at least one of claims 1 to 6, comprising
- a) linking a building block of the formula XI,




in which R_0 , Q, Q' and X, are as in claims 1 to 6, and R^1 , $R^{1''}$, $R^{1'''}$, $R^{1''''}$, are hydrogen atom or as R^1 as defined in claims 1 to 6, but where in R_0 , Q, R^1 Q' and X functional groups can also be present in protected form or in the form of precursor groups, and Y is a nucleophilically substitutable leaving group or a hydroxyl group, is reacted with a fragment of the formula III



in which R_{10} and V are as defined in claims 1 to 6, but where in R_{10} and V functional groups can also be present in protected form or in the form of precursor groups, or

- b) by coupling of a fragment of the formula XIII with fragment XII,



in which R_0 , Q, Q' and X, are as in claims 1 to 6, W is the substructure of formula III, but where in R_0 , Q, Q', W and X functional groups can also be present in protected form or in the form of precursor groups, and Y is a nucleophilically substitutable leaving group or a hydroxyl group

or a hydroxy group may be attached to a polystyrene resin.

8. (Amended) A pharmaceutical preparation, comprising at least one compound of the formula I as claimed in at least one of claims 1 to 6 and/or its physiologically tolerable salts and a pharmaceutically acceptable carrier.

9. (Amended) A pharmaceutical composition comprising a compound of the formula I as claimed in at least one of claims 1 to 6 and/or their physiologically tolerable salts and/or their prodrugs for inhibition of factor Xa and/or factor VIIa or for influencing blood coagulation or fibrinolysis.
10. (Amended) A method of treating blood coagulation disorders, inflammatory response, fibrinolysis, cardiovascular disorders, thromboembolic diseases, restenoses, abnormal thrombus formation, acute myocardial infarction, unstable angina, acute vessel closure associated with thrombolytic therapy, thromboembolism, percutaneous, pathologic thrombus formation occurring in the veins of the lower extremities following abdominal, knee and hip surgery, transluminal coronary angioplasty, transient ischemic attacks, stroke a risk of pulmonary thromboembolism, certain viral infections or cancer, intravascular coagulopathy occurring in vascular systems during septic shock, coronary heart disease, myocardial infarction, angina pectoris, vascular restenosis, for example restenosis following angioplasty like PTCA, adult respiratory distress syndrome, multi-organ failure, stroke and disseminated intravascular clotting disorder, thromboses like deep vein and proximal vein thrombosis which can occur following surgery comprising administration of the pharmaceutical composition of claim 9 to a host in need thereof.
11. (Amended) A prodrug of the compound of the formula I as claimed in at least one of claims 1 to 6.
12. (New) The (C₁-C₆)-acyl prodrug according to claim 11.
13. (New) The (C₁-C₆)-alkyloxycarbonyl prodrug according to claim 11.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

REMARKS

Please enter these amended claims. Support for the amendment is found in the claims as originally filed with the specification. No new matter is added.

If there is any fee due in connection with the filing of this Preliminary Amendment, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: December 6, 2001


By: Carol P. Einaudi
Carol P. Einaudi
Reg. No. 32,220

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

APPENDIX

1. (Amended) A compound of the formula I,



wherein

- R_0 is
1. phenyl, wherein phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^2 or
 2. a mono- or bicyclic 5- to 10-membered heteroaryl containing one or two nitrogen atoms as ring heteroatoms, wherein heteroaryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^2 ,
- R^2 is
1. $-NO_2$,
 2. halogen,
 3. $-CN$,
 4. $-OH$,
 5. $-NH_2$,
 6. (C_1-C_8) -alkyloxy-, wherein alkyloxy is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, amino group, hydroxy group or methoxy group, or
 7. $-(C_1-C_8)$ -alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, amino group, hydroxy group or methoxy group,

Q and Q' are independently of one another identical or different and are a direct bond, $-O-$, $-S-$, $-NR^{10}-$, $-C(O)NR^{10}-$, $-NR^{10}C(O)-$, $-S(O)-$, $-SO_2-$, $-NR^{10}-SO_2-$, $-SO_2-NR^{10}-$ [order] or $-C(O)-$;

R^{10} is hydrogen atom or (C_1-C_4) -alkyl-,

X is

1. a direct bond,


FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

2. (C₁-C₆)-[alkylen] alkylene, wherein [alkylen] alkylene is unsubstituted or mono-, di- or

trisubstituted independently of one another by halogen, amino group or a hydroxy group,

3. (C₃-C₆)-[cycloalkylen] cycloalkylene, wherein [cycloalkylen] cycloalkylene is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, amino group or a hydroxy group, provided that at least one of Q, X and Q' is not a direct bond, [D is an atom out of the group carbon, oxygen, sulfur and nitrogen,] the substructure of formula III



- is 1. a mono- or bicyclic 5- to 10-membered carbocyclic aryl group, wherein said 5- to 10-membered carbocyclic aryl group is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹,
2. phenyl, wherein phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹,
3. a mono- or bicyclic 5- to 10-membered heterocyclic group (Het), containing one or more heteroatoms as ring heteroatoms, such as nitrogen, sulfur or oxygen, wherein said Het group is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹, or
4. pyridyl, wherein pyridyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹,

wherein D is carbon, oxygen, sulfur or nitrogen,

- R¹ is
1. halogen,
 2. -NO₂,
 3. -CN,

105021 224007

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

4. $R^{11}R^{12}N-$, wherein $R^{11}R^{12}$ independently of one another are hydrogen atom, (C_1-C_4) -alkyl- or (C_1-C_6) -acyl-,
5. (C_1-C_8) -alkylamino-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{13} ,
6. $-OH$,
7. $-SO_2-NH_2$,
8. (C_1-C_8) -alkyloxy-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{13} ,
9. (C_6-C_{14}) -aryl, wherein aryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{13} ,
10. (C_1-C_8) -alkyl-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{13} ,
11. hydroxycarbonyl- (C_1-C_8) -alkylureido-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{13} ,
12. (C_1-C_8) -alkyloxycarbonyl- (C_1-C_8) -alkylureido-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{13} ,
13. (C_1-C_8) -alkylsulfonyl-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{13} , or
14. $-C(O)-NR^{14}R^{15}$, wherein $R^{14}R^{15}$ independently of one another are hydrogen atom or (C_1-C_4) -alkyl-, or

two R^1 residues bonded to adjacent ring carbon atoms together with the carbon atoms to which they are bonded form an aromatic ring condensed to the ring depicted in formula I, where the ring formed by the two R^1 residues is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{13} ,







R^{11} and R^{12} together with the nitrogen atom to which they are bonded form a saturated or unsaturated 5- to 6-membered monocyclic heterocyclic ring which in addition to the nitrogen atom carrying R^{11} and R^{12} can contain one or two identical or different ring heteroatoms chosen from oxygen, sulfur and nitrogen, and in which one or two of the ring carbon atoms can be substituted by oxo to form

$-C(O)-$ residue(s),

- R^{13} is
1. halogen,
 2. $-NO_2$,

3. -CN,
4. -OH,
5. (C₁-C₈)-alkyl-,
6. (C₁-C₈)-alkyloxy-,
7. -CF₃ or
8. -NH₂,

V is a residue of the formulae IIa, IIb, IIc, IId, IIe or IIf,



wherein

L is a direct bond or (C₁-C₃)-alkylene, wherein alkylene is unsubstituted or mono-, di- or trisubstituted independently of one another by A,

- A is
1. hydrogen atom,
 2. -C(O)-OH,
 3. -C(O)-O-(C₁-C₄)-alkyl, wherein alkyl is unsubstituted or mono-, di- or tri- substituted independently of one another by -OH, -NH₂ or -(C₁-C₄)-alkoxy,
 4. -C(O)-NR⁴R⁵,
 5. (C₁-C₄)-alkyl-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by -OH, -NH₂ or -(C₁-C₄)-alkoxy,
 6. -SO₂-NH₂ or

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

7. -SO₂-CH₃,

U is -NH₂, (C₁-C₄)-alkyl-, -NH-C(O)-O-(C₁-C₄)-alkyl or
-NH-C(O)-O-(C₁-C₄)-alkyl-aryl,

M is hydrogen atom, (C₁-C₃)-alkyl- or -OH,

R⁴ and R⁵ are independently of one another identical or different and are

1. hydrogen atom,
2. (C₁-C₁₂)-alkyl-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³ as defined above,
3. (C₆-C₁₄)-aryl-(C₁-C₄)-alkyl-, wherein alkyl and aryl are unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³ as defined above,
4. (C₆-C₁₄)-aryl-, wherein aryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³ as defined above,
5. Het-, wherein Het- is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³ as defined above, or
6. Het-(C₁-C₄)-alkyl-, wherein alkyl and Het- are unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³ as defined above, or

R⁴ and R⁵ together with the nitrogen atom to which they are bonded form a saturated 3- to 8-membered monocyclic heterocyclic ring which in addition to the nitrogen atom carrying R⁴ and R⁵ can contain one or two identical or different ring heteroatoms chosen from oxygen, sulfur and nitrogen;

in all its stereoisomeric forms and mixtures thereof in any ratio, and its physiologically tolerable salts.

2. (Amended) A compound of formula I as claimed in claim 1, wherein

R₀ is phenyl, wherein phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R², or
pyridyl, wherein pyridyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R²,

- R² is
1. -NO₂,
 2. halogen,

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

3. -CN,
4. -OH,
5. -NH₂,
6. (C₁-C₄)-alkyloxy-, wherein alkyloxy is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, amino group, hydroxy group or methoxy group, or
7. -(C₁-C₄)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, amino group, hydroxy group or methoxy group,

Q, Q', X, R¹, R¹¹ and R¹² are as defined in claim 1,

[D is an atom out of the group carbon and nitrogen,]

the substructure of formula III is

1. phenyl, wherein phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹, or
2. pyridyl, wherein pyridyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹,

wherein D is carbon or nitrogen,

- R¹³ is
1. halogen,
 2. -NO₂,
 3. -CN,
 4. -OH,
 5. (C₁-C₄)-alkyl-,
 6. (C₁-C₄)-alkyloxy-,
 7. -CF₃ or
 8. -NH₂,

R₁₀ is hydrogen atom or methyl,

V is a fragment of the formula IIa, IIb, IIc, IId, IIe or II f as defined above, wherein

L, U, M, R⁴ and R⁵ are as defined in claim 1, and

- A is
1. hydrogen atom,
 2. -C(O)-OH,
 3. -C(O)-O-(C₁-C₄)-alkyl, wherein alkyl is unsubstituted or mono-, di- or tri- substituted independently of one another by -OH, -NH₂ or -(C₁-C₄)-alkoxy,

T09027 " 22440001

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

4. $-C(O)-NR^4R^5$ or
5. (C_1-C_4) -alkyl-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by $-OH$, $-NH_2$ or $-(C_1-C_4)$ -alkoxy.

3. (Amended) A compound of the formula I as claimed in [claims 1 or 2] claim 1, wherein

R^0 is phenyl, wherein phenyl is mono-, di- or trisubstituted independently of one another by R^2 , or
pyridyl, wherein pyridyl is mono-, di- or trisubstituted independently of one another by R^2 ,

- R^2 is
1. $-NH_2$,
 2. halogen,
 3. $-CN$,
 4. $-OH$,
 5. (C_1-C_4) -alkyloxy-, wherein alkyloxy is unsubstituted or substituted by an amino group, or
 6. $-(C_1-C_4)$ -alkyl, wherein alkyl is unsubstituted or substituted by an amino group,

Q and Q' are independently of one another identical or different and are a direct bond, $-O-$, $-C(O)NR^{10}-$, $-NR^{10}C(O)-$; $-NR^{10}-SO_2-$; or $-SO_2-NR^{10}-$;

- X is
1. a direct bond or
 2. (C_1-C_4) -[alkylen] alkylene, wherein [alkylen] alkylene is unsubstituted or mono-, di- or tri-substituted independently of one another by halogen, amino group or a hydroxy group,

[D is an atom out of the group carbon and nitrogen,]

the substructure of formula III is

phenyl or pyridyl, wherein phenyl and pyridyl are unsubstituted or mono-, di- or trisubstituted independently of one another by R^1 , and

D is carbon or nitrogen,

- R^1 is
1. halogen,
 2. $-NO_2$,

F03021 2240001

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

3. -CN,
 4. -NH₂,
 5. (C₁-C₄)-alkylamino-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
 6. -OH,
 7. -SO₂-NH₂,
 8. (C₁-C₄)-alkyloxy-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
 9. (C₆-C₁₄)-aryl, wherein aryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
 10. (C₁-C₄)-alkyl-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
 11. (C₁-C₄)-alkylsulfonyl-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
 12. -C(O)-NR¹⁴R¹⁵, wherein R¹⁴R¹⁵ independently of one another are hydrogen atom or (C₁-C₄)-alkyl-,
 13. R¹¹R¹²N-, wherein R¹¹ and R¹² are as defined above, or
 14. -NR⁴R⁵,
- R¹³ is
1. halogen,
 2. -NO₂,
 3. -CN,
 4. -OH,
 5. (C₁-C₄)-alkyl-,
 6. (C₁-C₄)-alkyloxy-,
 7. -CF₃ or
 8. -NH₂,

R₁₀ is hydrogen atom or methyl,

V is a fragment of the formula IIa, IIb, IIc, IId, IIe or II f as defined above, wherein

L is a direct bond or (C₁-C₃)-alkylen-,

A is hydrogen atom, -C(O)-OH, -C(O)-O-(C₁-C₄)-alkyl, -C(O)-NR⁴R⁵ or (C₁-C₄)-alkyl-,

U is -NH₂, methyl, -NH-C(O)-O-(C₁-C₄)-alkyl or -NH-C(O)-O-(CH₂)-phenyl,

M is hydrogen atom, (C₁-C₃)-alkyl- or -OH, and

R⁴ and R⁵ are independently of one another hydrogen atom or (C₁-C₄)-alkyl-.

4. (Amended) A compound of formula I as claimed in [one or more of claims 1 to 3] claim 1, wherein

R₀ is phenyl or pyridyl, wherein phenyl and pyridyl independently from one another are mono-, di- or trisubstituted independently of one another by R²,

R² is

1. halogen,
2. -CN,
3. (C₁-C₄)-alkyloxy-, wherein alkyloxy is unsubstituted or substituted by halogen or an amino group, or
4. -(C₁-C₄)-alkyl, wherein alkyl is unsubstituted or substituted by an amino group or halogen,

Q and Q' are independently of one another identical or different and are a direct bond, -O-, -C(O)NR¹⁰-, -NR¹⁰C(O)-; -NR¹⁰-SO₂-; or -SO₂-NR¹⁰-;

X is -(C₁-C₃)-alkylen-, wherein alkylen is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, amino group or hydroxy group,

[D is the atom carbon,]

the substructure of formula III is

phenyl, wherein phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹, and

D is carbon

R¹ is

1. halogen,
2. -NO₂,
3. -CN,
4. -NH₂,
5. (C₁-C₄)-alkylamino-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
6. -OH,
7. -SO₂-NH₂,
8. (C₁-C₄)-alkyloxy-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,

FOOET 244000

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

9. (C₆-C₁₄)-aryl, wherein aryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
10. (C₁-C₄)-alkyl-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
11. (C₁-C₄)-alkylsulfonyl-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
12. -C(O)-NR¹⁴R¹⁵, wherein R¹⁴R¹⁵ independently of one another are hydrogen atom or (C₁-C₄)-alkyl-,
13. R¹¹R¹²N-, wherein R¹¹ and R¹² are as defined above, or
14. -NR⁴R⁵,

- R¹³ is
1. halogen,
 2. -CF₃,
 3. -NH₂,
 4. -OH,
 5. (C₁-C₄)-alkyl- or
 6. (C₁-C₄)-alkyloxy-,

R₁₀ is hydrogen atom, and

V is a fragment of the formula IIa, IIb, IIc or IId as defined above, wherein

L is a direct bond or (C₁-C₂)-alkylen-,

A is hydrogen atom, -C(O)-OH, -C(O)-O-(C₁-C₄)-alkyl, -C(O)-NR⁴R⁵ or (C₁-C₄)-alkyl,

U is -NH₂, methyl, -NH-C(O)-O-(C₁-C₄)-alkyl or -NH-C(O)-O-(CH₂)-phenyl,

M is hydrogen atom or (C₁-C₃)-alkyl-, and

R⁴ and R⁵ are independently of one another hydrogen atom or methyl.

5. (Amended) A compound of formula I as claimed in [one or more of claims 1 to 4] claim 1, wherein

R₀ is phenyl, wherein phenyl is mono-, di- or trisubstituted independently of one another by R²,

R² is

1. halogen,

2. (C₁-C₄)-alkyloxy-, wherein alkyloxy is unsubstituted or substituted by halogen or an amino group, or
3. -(C₁-C₄)-alkyl, wherein alkyl is unsubstituted or substituted by an amino group or halogen,

Q and Q' are independently of one another identical or different and are a direct bond, -O-, -C(O)NR¹⁰-, -NR¹⁰C(O)-; -NR¹⁰-SO₂-; or -SO₂-NR¹⁰-;

X is -(C₁-C₃)-alkylen-,

[D is the atom carbon,]

the substructure of formula III is

phenyl, wherein phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹, and

D is carbon

- R¹ is
1. halogen,
 2. -NO₂,
 3. -CN,
 4. -NH₂,
 5. (C₁-C₄)-alkylamino-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
 6. -OH,
 7. -SO₂-NH₂,
 8. (C₁-C₄)-alkyloxy-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
 9. (C₁-C₄)-alkyl-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
 10. (C₁-C₄)-alkylsulfonyl-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
 11. -C(O)-NR¹⁴R¹⁵, wherein R¹⁴R¹⁵ independently of one another are hydrogen atom or (C₁-C₂)-alkyl-,
 12. R¹¹R¹²N-, wherein R¹¹ and R¹² are as defined above, or
 13. -NR⁴R⁵,

- R¹³ is
1. halogen,
 2. -CF₃,
 3. -NH₂,

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

4. -OH,
5. (C₁-C₄)-alkyl- or
6. (C₁-C₄)-alkyloxy-,

R₁₀ is hydrogen atom, and

V is a fragment of the formula IIa, IIb, IIc or IId as defined above, wherein

L is a direct bond or (C₁-C₂)-alkylen-,

A is hydrogen atom, -C(O)-OH, -C(O)-O-(C₁-C₄)-alkyl, -C(O)-NR⁴R⁵ or
-(C₁-C₄)-alkyl,

U is -NH₂, methyl, -NH-C(O)-O-(C₁-C₄)-alkyl or -NH-C(O)-O-(CH₂)-phenyl,

M is hydrogen atom or methyl, and

R⁴ and R⁵ are independently of one another hydrogen atom or methyl.

6. (Amended) A compound of formula I as claimed in [one or more of claims 1 to 5]
claim 1, wherein

R₀ is phenyl, wherein phenyl is disubstituted independently of one another by R²,

- R² is
1. halogen,
 2. (C₁-C₂)-alkyloxy-, wherein alkyloxy is unsubstituted or substituted by an amino group, or
 3. -(C₁-C₄)-alkyl, wherein alkyl is unsubstituted or substituted by an amino group,

Q and Q' are independently of one another identical or different and are
a direct bond or -O-,

X is -CH₂-CH₂-,

[D is the atom carbon,]

the substructure of formula III is

phenyl, wherein phenyl is unsubstituted or mono-, di- or trisubstituted
independently of one another by R¹, and

D is carbon,

- R¹ is
1. halogen,
 2. -OH,
 3. -NH₂,

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

4. $-\text{C}(\text{O})-\text{NR}^{14}\text{R}^{15}$, wherein $\text{R}^{14}\text{R}^{15}$ independently of one another are hydrogen atom or (C_1-C_2) -alkyl-,
5. (C_1-C_3) -alkyloxy-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{13} , or
6. (C_1-C_3) -alkyl-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{13} ,

R^{13} is fluorine or chlorine,

R_{10} is hydrogen atom, and

V is a fragment of the formula IIa, IIb, IIc or IId as defined above, wherein

L is a direct bond or (C_1-C_2) -alkylen-,


A is hydrogen atom, $-\text{C}(\text{O})-\text{OH}$, $-\text{C}(\text{O})-\text{O}-(\text{C}_1-\text{C}_4)$ -alkyl, $-\text{C}(\text{O})-\text{NR}^4\text{R}^5$ or $-(\text{C}_1-\text{C}_4)$ -alkyl,

U is $-\text{NH}_2$, methyl, $-\text{NH}-\text{C}(\text{O})-\text{O}-(\text{C}_1-\text{C}_4)$ -alkyl or $-\text{NH}-\text{C}(\text{O})-\text{O}-(\text{CH}_2)$ -phenyl,

M is hydrogen atom, and


R^4 and R^5 are independently of one another hydrogen atom or methyl.

7. (Amended) A process for the preparation of a compound of the formula I as claimed in at least one of claims 1 to 6, [comprises] comprising
 - a) linking a building block of the formula XI,




in which R_0 , Q, Q' and X, are as in claims 1 to 6, and $\text{R}^{1'}$, $\text{R}^{1''}$, $\text{R}^{1'''}$, $\text{R}^{1''''}$, are hydrogen atom or as R^1 as defined in claims 1 to 6, but where in R_0 , Q, R^1 Q' and X functional groups can also be present in protected form or in the form of precursor groups, and Y is a nucleophilically [substitutable] substitutable leaving group or a hydroxyl group,

is reacted with a fragment of the formula III



in which R₁₀ and V are as defined in claims 1 to 6, but where in R₁₀ and V functional groups can also be present in protected form or in the form of precursor groups, or

b) by coupling of a fragment of the formula XIII with fragment XII,



in which R₀, Q, Q' and X, are as in claims 1 to 6, W is the substructure of formula III, but where in R₀, Q, Q', W and X functional groups can also be present in protected form or in the form of precursor groups, and Y is a nucleophilically substituable leaving group or a hydroxyl group
or a hydroxy group may be attached to a polystyrene resin.

8. (Amended) A pharmaceutical preparation, comprising at least one compound of the formula I as claimed in at least one [or more] of claims 1 to 6 and/or its physiologically tolerable salts and a pharmaceutically acceptable carrier.
9. (Amended) [The use of] A pharmaceutical composition comprising a compound of the formula I as claimed in at least one [or more] of claims 1 to 6 and/or their physiologically tolerable salts and/or their prodrugs [for the production of pharmaceuticals] for inhibition of factor Xa and/or factor VIIa or for influencing blood coagulation or fibrinolysis.
10. (Amended) A method of treating [The use as claimed in claim 9 for influencing] blood coagulation disorders, inflammatory response, fibrinolysis, cardiovascular disorders, thromboembolic diseases, restenoses, abnormal thrombus formation, acute myocardial infarction, unstable angina, acute vessel closure associated with thrombolytic therapy, thromboembolism, percutaneous, pathologic thrombus formation occurring in the veins of the lower extremities following abdominal, knee and hip surgery, transluminal coronary angioplasty, transient ischemic attacks, stroke a risk of pulmonary thromboembolism, certain viral infections or cancer, intravascular coagulopathy occurring in vascular systems during septic shock, coronary heart disease, myocardial infarction, angina pectoris, vascular restenosis, for example restenosis following angioplasty like PTCA, adult respiratory distress syndrome, multi-organ failure, stroke and disseminated intravascular clotting disorder,

T03021 224000T

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

thromboses like deep vein and proximal vein thrombosis which can occur following surgery comprising administration of the pharmaceutical composition of claim 9 to a host in need thereof.

11. (Amended) A prodrug of the compound of the formula I as claimed in at least one of claims 1 to 6[, preferably a (C₁-C₆)-acyl or (C₁-C₆)-alkyloxycarbonyl prodrugs of the compound of the formula I as claimed in claims 1 to 6].

TO SECRETARY

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com